Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.22 EUR | -0.42% | -3.92% | -13.61% |
Apr. 11 | Eurobio Scientific: 2023 results down, share price falls | CF |
Jan. 30 | Eurobio Scientific Société anonyme acquired Alpha Biotech Ltd. | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 33.07 times its 2023 earnings per share.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.61% | 156M | - | ||
+1.77% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.24% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.44% | 25.49B | B- | ||
-23.01% | 18.12B | B | ||
+30.56% | 12.24B | C+ | ||
-1.82% | 11.76B | C+ | ||
+8.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALERS Stock
- Ratings Eurobio Scientific